William Blair Has Pessimistic Outlook of NAMS Q4 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at William Blair cut their Q4 2024 earnings per share estimates for NewAmsterdam Pharma in a research note issued on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will earn ($0.51) per share for the quarter, down from their prior estimate of ($0.39). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. William Blair also issued estimates for NewAmsterdam Pharma’s Q1 2025 earnings at ($0.49) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.99) EPS, FY2026 earnings at ($2.07) EPS and FY2027 earnings at ($2.32) EPS.

A number of other research firms have also recently commented on NAMS. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, November 7th. Finally, Piper Sandler restated an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $33.80.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $24.76 on Monday. NewAmsterdam Pharma has a one year low of $8.64 and a one year high of $26.35. The company’s 50-day moving average is $17.83 and its 200 day moving average is $18.50.

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HealthInvest Partners AB lifted its holdings in NewAmsterdam Pharma by 83.4% during the third quarter. HealthInvest Partners AB now owns 138,983 shares of the company’s stock valued at $2,307,000 after purchasing an additional 63,189 shares in the last quarter. Jennison Associates LLC raised its position in shares of NewAmsterdam Pharma by 8.9% during the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after purchasing an additional 83,115 shares during the period. GSA Capital Partners LLP lifted its stake in shares of NewAmsterdam Pharma by 79.9% during the 3rd quarter. GSA Capital Partners LLP now owns 66,402 shares of the company’s stock valued at $1,102,000 after buying an additional 29,496 shares in the last quarter. Lisanti Capital Growth LLC bought a new position in NewAmsterdam Pharma in the 3rd quarter worth $700,000. Finally, TimesSquare Capital Management LLC boosted its holdings in NewAmsterdam Pharma by 3.7% in the 3rd quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock worth $4,237,000 after buying an additional 9,160 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 19.50% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.